REPLIMUNE GROUP INC (REPL)
Health Care · NASDAQ
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in combination therapy for melanoma patients who have failed checkpoint inhibitors.
What REPLIMUNE GROUP INC does
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies based on its proprietary RPx platform, an engineered herpes simplex virus 1 (HSV-1) backbone designed to directly kill tumors and trigger systemic anti-tumor immune responses. The company's lead candidate, RP1 (vusolimogene oderparepvec), is being evaluated in combination with checkpoint inhibitors, particularly anti-PD-1 therapy, with a focus on establishing a skin cancer treatment franchise. Replimune's approach bundles multiple mechanisms of action into "off-the-shelf" therapies intended to maximize immunogenic cell death and be synergistic with established cancer treatments.
Themes: ["oncolytic immunotherapy"]
Fundamentals
- Price$11.11 as of 2026-07-09 close
- Market cap$928M as of 2026-07-10
- 1-year return+6.9% as of 2026-07-09 close
- ROE-128.6% as of 2026-07-10
- Debt / equity0.65 as of 2026-07-10
- Beta0.89 as of 2026-07-10
Key risks (from latest filing)
["FDA regulatory setback: RP1 BLA for advanced melanoma received a Complete Response Letter (CRL) on July 21, 2025, with FDA stating the IGNYTE trial did not provide substantial evidence of effectiveness and citing patient population heterogeneity as a concern, requiring additional development and regulatory negotiations."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.